Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
|Articles|August 24, 2015
D. Ross Camidge on the Development of a New Lung Cancer Drug
Author(s)D. Ross Camidge
D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK).
Advertisement
D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of
Camidge presented results from a study of brigatinib during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of nearly 30,000 oncology professionals in Chicago.
Advertisement
Related to this article
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Bravnetsa, an Equivalent to Lutathera, for GEP-NETs
2
Finding the Words: How to Talk to Someone With Cancer
3
Cancer Research Is Looking Beyond the Tumor to Better Understand the Whole Patient
4
3 More Lung Cancer Breakthroughs From WCLC 2026
5